By Caroline Pearson, VP, Avalere Health LLC & Tanisha Carino, EVP, Avalere Health LLC
science are ushering in a wave of targeted drugs and biopharmaceuticals that
deliver more precise and predictable outcomes to patients with fewer toxic side
effects. But such products often come with higher prices. Purchasers are
grappling with whether and how to cover these expensive drugs and are
increasingly shifting the cost to patients who incur potentially unaffordable
high out-of-pocket costs.
proposing a decision matrix to help both payers and manufacturers evaluate the
value of new drugs and define the type of financing options that will make
these treatments accessible to patients.